#AANAM – Promising Blood Pressure Medicine Fails to Slow Parkinson’s Progression, Trial Results Show

In contrast to what was observed in mice, a hypertension medicine called Dynacirc (isradipine) failed to slow Parkinson’s disease progression in humans, according to Phase 3 clinical trial results. However, “the study did not fail,” according to Tanya Simuni, MD, who presented “A Phase 3 study of…

Hypertension Medicine in Phase 3 Parkinson’s Trial Seen to Protect Nerve Cells of Mice from Damage

Use of a hypertension treatment called Dynacirc (isradipine) — a calcium channel blocker — eased the type of nerve cell damage seen in Parkinson’s disease, a mouse study reports. These preclinical findings support an ongoing Phase 3 trial (NCT02168842), known as STEADY-PD III, that is evaluating Dynacirc’s potential to…